Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 43, Issue , 1999, Pages

  Dixon, Shannon C ^a   Kruger, Erwin A ^a   Bauer, Ken S ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cDNA array; LNCaP cells; PC 3 cells; PSA; Thalidomide

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

ANTIGEN EXPRESSION; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; CONFERENCE PAPER; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS REGULATION; TUMOR VASCULARIZATION;

EID: 0032983205     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051103     Document Type: Conference Paper

References (35)

1. Allhoff EP, Proppe KH, Chapman CM, Lin C-H, Prout GF Jr. Evaluation or prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 129: 315
2. Barnhill RI, McDougal AC (1982) Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 7: 317
3. Bauer KS, Dixon SC, Figg WD (1998) Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 55: 1827
4. Brooks PC, Clark RAF, Cheresh DA (1994) Requirement of vascular integrin alpha-v beta-3 for angiogenesis. Science 264: 569
5. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S (1995) Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866
6. Clements JA (1989) The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocrinol Rev 10: 393
7. Czejka MJ, Koch HP (1987) Determination of thalidomide and its major metabolites by high-performance liquid chromatography. J Chromatogr 413: 181
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082
9. Folkman J (1990) What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82: 4
10. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct alpha-v integrins. Science 270: 1500
11. Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324: 236
12. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V (1981) Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci USA 78: 2545
13. Grosshans E, Illy G (1984) Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 23: 598
14. Günzler V (1992) Thalidomide in human immunodeficiency virus patients. Drug Safety 7: 116
15. Günzler V, Hanauske-Abel HM, Tschank G, Schutz-Wisserman H (1986) Immunological effects of thalidomide: Inactivity of the drug and several of its hydrolysis products in mononucleocyte proliferation tests. Arzneim-Forsch Drug Res 36: 1138
16. Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O (1989) Treatment of refractory rheumatoid arthritis - the thallidomide experience. J Rheumatol 16: 158
17. Gutman M, Szold A, Ravid A, Lazzauskas T, Merimsky O, Klausner JM (1996) Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 16: 3673
18. Hastings RC (1980) Kellersberger Memorial lecture 1979: immunosuppressive/anti-inflammatory thalidomide analogues. Ethiop Med J 18: 65
19. Hendler SS, McCarth MF (1983) Thalidomide for autoimmune disease. Med Hypotheses 10: 437
20. Koch HP (1985) Thalidomide and congeners as anti-inflammatory agents. Prog Med Chem 22: 166
21. Lenz W (1962) Thalidomide and congenital abnormalities. Lancet i: 45
22. McBride WG (1961) Thalidomide and congenital abnormalities. Lancet ii: 1358
23. McCarty MF (1997) Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utitlity in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 49: 123
24. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schauf V, Kaplan G (1993) Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90: 5974
25. Moreira AL, Sampaio EP, Zmuidzina A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675
26. Neubert R, Nogueira AC, Neubert D (1992) Thalidomide and the immune system. 2: Changes in receptors on blood cells of a healthy volunteer. Life Sci 51: 2107
27. Neubert R, Nogueira AC, Neubert D (1993) Thalidomide derivatives and the immune system. I: Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 67: 1
28. Neubert R, Hinz N, Thiel R, Neubert D (1996) Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58: 295
29. Nogueira AC, Neubert R, Helge H, Neubert D (1994) Thalidomide and the immune system. 3: Simultaneous up-and down-regulation of different integrin receptors on human white blood cells. Life Sci 55: 77
30. Pollard M (1996) Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats. Cancer Lett 101: 21
31. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173: 699
32. Sheskin J (1965) Thalidomide in treatment of lepra reactions. Clin Pharmacol Ther 6: 303
33. Simmons BR, Lush RM, Figg WD (1997) A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Anal Chim Acta 339: 91
34. Winckler K, Klinkmüller KD, Schmahl HJ (1989) Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yle)-phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples. J Chromatogr 448:417
35. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326: 1055